Industry, FDA Outline Costs Of New MDUFA Proposals; Quality Management A Strong Focus
This article was originally published in Clinica
Executive Summary
After months of discussing proposals on how to improve FDA's device review process in the next user-fee reauthorization (MDUFA IV), the agency put some hard numbers to how much the proposed measures would cost and how many full-time equivalent positions would be required. In total, the agency puts the price tag of the reforms at $500 million over five years on top of the current user fee base, not taking into account inflation.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.